Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
1.020
-0.050 (-4.67%)
At close: Jan 8, 2025, 4:00 PM
1.030
+0.010 (0.95%)
After-hours: Jan 8, 2025, 5:46 PM EST
Adial Pharmaceuticals Employees
As of December 31, 2023, Adial Pharmaceuticals had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees decreased by 13 or -65.00% compared to the previous year.
Employees
7
Change (1Y)
-13
Growth (1Y)
-65.00%
Revenue / Employee
n/a
Profits / Employee
-$1,863,856
Market Cap
6.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ADIL News
- 5 weeks ago - Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire